Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Pandoraon Nov 04, 2022 3:01pm
247 Views
Post# 35074117

RE:RE:RE:Another look at the data

RE:RE:RE:Another look at the data
DJDawg wrote:
I know everyone is hopeful that that 25 is the magic number for BTD submission but I would argue that it is not so simple. The FDA info says that as you get closer you can request a meeting to discuss whether the data is enough to get BTD. Kind of a way of checking in and getting a preliminary thumbs up vs being told that should aim for another x number of patients and a total CR of x %.

As such, I believe that 25 is the point where they will check in and utilize this pre-BTD application meeting option. If they get told to collect a few more patient data points it is not necessarily a bad thing as it means that when apply for BTD it is more likely to succeed. Or maybe they have already had this meeting check in. Who knows?


I would like to see them take those 12 "undertreated" patients out of the data base completely and write them off as what they are - a mistake! That is very unlikely to happen but their numbers muck up all numbers for evermore, whether it be 12 out of 25 or 12 out of 100 they distort the true result.
Question then is - do the reviewers work around them? imho.
<< Previous
Bullboard Posts
Next >>